stockrow
Monday 9 November 2026
Export WHWK’s income statement to Excel — free account
Whitehawk Therapeutics, Inc.
WHWKWhitehawk Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.1 million, down 72.5% from fiscal 2024.
- Revenue
- +33.5%
- EPS
- +73.7%
- Free cash flow
- +72.6%
Quarter to June 2026, against a year earlier
3.13
0.11
+3.64%
Follow WHWK
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | 20 | — | 15 | 1 | 15 | 24 | 26 | 7 | 28 | (13.8%) | — | — | — | — | |
| Gross margin, % | 0.00 | 0.00 | 100.00 | 0.00 | 100.00 | 100.00 | 91.23 | 88.47 | 88.36 | 89.36 | 88.72 | +89.4 pt | ||||||
| EBT | (17) | (21) | (10) | (23) | (3) | (110) | (61) | (66) | (64) | (21) | (80) | +2.2% | ||||||
| EBT margin, % | 0.00 | 0.00 | (51.58) | 0.00 | (23.84) | (9,829.29) | (397.69) | (270.04) | (245.13) | (288.26) | 0.00 | (288.3) pt | ||||||
| Net income | (17) | (21) | (10) | (23) | (3) | (110) | (61) | (66) | (64) | (21) | (80) | +2.2% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 8.91 | 0.00 | 5.74 | 0.13 | 0.68 | 0.90 | 0.96 | 0.12 | 0.00 | n/m | |||||
| Earnings | (367.88) | (14.80) | (4.65) | (8.55) | (1.76) | (12.41) | (2.69) | (2.44) | (2.36) | (0.33) | (1.12) | (54.1%) | ||||||
| Cash flow | (276.24) | (13.06) | (2.57) | (8.81) | (5.00) | (2.51) | (2.21) | (2.22) | (2.20) | (1.57) | (0.84) | (43.7%) | ||||||
| Capex | (1.99) | (0.01) | (0.02) | (0.09) | (0.01) | (0.01) | (0.02) | (0.15) | (0.06) | (0.01) | 0.00 | (45.2%) | ||||||
| Free cash flow | (278.23) | (13.07) | (2.58) | (8.90) | (5.00) | (2.52) | (2.22) | (2.36) | (2.26) | (1.58) | (0.84) | (43.7%) | ||||||
| Book value | (1,515.27) | 12.06 | 25.92 | 13.50 | (4.89) | 15.29 | 7.04 | 3.91 | 1.94 | 2.20 | 2.21 | n/m | ||||||
| Shares, m | 0 | 1 | 2 | 3 | 3 | 9 | 23 | 27 | 27 | 62 | 71 | +117.5% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.04 | 0.00 | 0.7 | |||||
| P/S | — | — | 0.00 | — | 2.56 | 307.88 | 18.21 | 2.27 | 3.29 | 5.39 | 9.34 | 48.5 | ||||||
| P/B | — | — | 0.98 | — | 0.00 | 1.58 | 1.75 | 0.52 | 1.63 | 1.10 | 1.42 | 1.1 | ||||||
| EV/Sales | — | — | 0.00 | — | 2.33 | 96.61 | 6.94 | (2.16) | 1.51 | 0.19 | 2.54 | 15.1 | ||||||
| EV/FCF | — | — | 0.84 | — | (2.67) | (3.00) | (2.11) | 0.83 | (0.64) | (0.05) | (1.01) | (1.0) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (16) | (19) | (6) | (24) | (13) | (22) | (50) | (60) | (60) | (97) | (69) | +22.5% | |||||
| Capex | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (4) | (2) | (1) | (1) | +19.2% | ||||||
| Free cash flow | (16) | (19) | (6) | (24) | (13) | (22) | (50) | (64) | (61) | (98) | (69) | +22.5% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | (13) | 17 | 59 | 36 | (11) | 136 | 161 | 98 | 44 | 134 | 181 | n/m | |||||
| Net debt | (2) | (20) | (63) | (38) | (3) | (149) | (173) | (109) | (47) | (146) | (190) | +64.4% | ||||||
| Shareholders’ equity | (86) | 17 | 59 | 37 | (12) | 136 | 158 | 105 | 52 | 136 | 183 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (1,731.56) | (190.77) | (24.42) | (44.73) | (15.20) | (125.31) | (35.37) | (41.54) | (62.83) | (18.63) | (42.60) | +1,712.9 pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (804.45) | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | 48.40 | 64.97 | (27.32) | (48.89) | (37.05) | (178.65) | (41.06) | (49.90) | (80.79) | (21.82) | (44.98) | (70.2) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | 25 | 27 | 11 | 12 | 39 | 79 | 89 | 40 | 23 | — | (1.0%) | |||||
| Revenue/emp, $m | — | 0.00 | 0.75 | 0.00 | 1.22 | 0.03 | 0.19 | 0.27 | 0.65 | 0.31 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Mar 2025 · fundamentals updated 26 Oct 2026
Whitehawk Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| TRDA Entrada Therapeutics, Inc. | $191.5M | — (loss-making) | — (loss-making) | −43.93% (below 0%: shrinking) | n/m | −7.05% (below 0%: shrinking) | 100.00% | (4,606.52%) | Compare |
| CGEN Compugen Ltd. | $185.7M | 5.2× | — (loss-making) | +107.00% (above 0%: growing) | n/m | −155.42% (below 0%: shrinking) | (3.54%) | (339.62%) | Compare |
| MDWD MediWound Ltd. | $184.0M | — (loss-making) | — (loss-making) | −45.83% (below 0%: shrinking) | n/m | −49.90% (below 0%: shrinking) | 10.90% | (305.89%) | Compare |
| BCYC Bicycle Therapeutics PLC Sponsored ADR | $182.5M | — (loss-making) | — (loss-making) | +190.24% (above 0%: growing) | n/m | +43.48% (above 0%: growing) | 100.00% | (39.57%) | Compare |
| ACOG Alpha Cognition Inc. | $180.5M | — (loss-making) | — (loss-making) | +267.56% (above 0%: growing) | n/m | −109.25% (below 0%: shrinking) | 94.80% | (127.29%) | Compare |
| WHWK Whitehawk Therapeutics, Inc. | $178.4M | — (loss-making) | — (loss-making) | +33.48% (above 0%: growing) | n/m | +72.57% (above 0%: growing) | 89.36% | 0.00% | |
| UPB Upstream Bio, Inc. | $176.9M | — (loss-making) | — (loss-making) | −17.50% (below 0%: shrinking) | n/m | +9.33% (above 0%: growing) | 100.00% | (5,480.98%) | Compare |
| IVVD Invivyd, Inc. | $166.0M | — (loss-making) | — (loss-making) | +21.20% (above 0%: growing) | n/m | −226.89% (below 0%: shrinking) | 91.09% | (320.76%) | Compare |
| BBOT BridgeBio Oncology Therapeutics, Inc | $163.6M | — (loss-making) | — | — | n/m | −88.78% (below 0%: shrinking) | — | 0.00% | Compare |
| Median of peers | $181.5M | — | — | +21.20% | — | −69.34% | 94.80% | (313.32%) |
Pay and ownership Proxy statement filed 28 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 3.40m | 4.49m | 18.86 |
Ownership
Directors and executive officers, together
49.90%
Entities Affiliated with Avoro
19.90%
Behzad Aghazadeh, Ph.D.
19.90%
Entities Affiliated with Ally Bridge Group
9.90%
Entities Affiliated with Suvretta
9.90%
OrbiMed Advisors LLC
8.40%
Anupam Dalal, M.D.
7.20%
Entities Affiliated with Acuta Capital Partners
6.90%
Coastlands Capital LP
5.70%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement